Clinically important features of porphyrin and heme metabolism and the porphyrias

Metabolites

Volumn 4, Issue 4, 2014, Pages 977-1006

  Besur, Siddesh ^a   Hou, Wehong ^a   Schmeltzer, Paul ^a   Bonkovsky, Herbert L ^b,c  

^a LEVINE CANCER INSTITUTE   (United States)

^b University of CT Medical Center   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

5 aminolevulinic acid; Heme; Iron; Metalloporphyrins; Mitochondria; Porphobilinogen; Porphyrias; porphyrins

Indexed keywords

5 AMINOLEVULINATE SYNTHASE; CHLORPROMAZINE; COPROPORPHYRINOGEN OXIDASE; CYTOCHROME P450 1A2; ETIRACETAM; FERROCHELATASE; GABAPENTIN; HEME OXYGENASE; IRON; METALLOPORPHYRIN; NARCOTIC ANALGESIC AGENT; ONDANSETRON; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHENOTHIAZINE; PORPHOBILINOGEN; PORPHOBILINOGEN DEAMINASE; PORPHOBILINOGEN SYNTHASE; PREGNANE X RECEPTOR; PROMETHAZINE; PROTOPORPHYRIN ZINC; UROPORPHYRINOGEN DECARBOXYLASE; VIGABATRIN;

5' UNTRANSLATED REGION; ACUTE INTERMITTENT PORPHYRIA; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; BIOSYNTHESIS; CARDIOVASCULAR SYMPTOM; CATABOLISM; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CONGENITAL ERYTHROPOIETIC PORPHYRIA; COPROPORPHYRIA; DECARBOXYLATION; ERYTHROPOIETIC PROTOPORPHYRIA; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HEME SYNTHESIS; HEPATIC PORPHYRIA; HEPATOERYTHROPOIETIC PORPHYRIA; HORMONE RELEASE; HUMAN; METABOLIC REGULATION; MITOCHONDRIAL MEMBRANE; MRNA EXPRESSION ASSAY; NEUROLOGIC DISEASE; PATHOGENESIS; PORPHYRIA; PORPHYRIA CUTANEA TARDA; PORPHYRIA VARIEGATA; PORPHYRIN METABOLISM; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

EID: 85016489978     PISSN: None     EISSN: 22181989     Source Type: Journal    
DOI: 10.3390/metabo4040977     Document Type: Article

References (115)

1. Li, M.; Vizzard, M.A.; Jaworski, D.M.; Galbraith, R.A. The weight loss elicited by cobalt protoporphyrin is related to decreased activity of nitric oxide synthase in the hypothalamus. J. Appl. Physiol. 2006, 100, 1983-1991.
2. Galbraith, R.A.; Hodgdon, I.; Grimm, M.S.; Vizzard, M.A. Prolonged retention of the anorectic cobalt protoporphyrin in the hypothalamus and the resulting expression of Fos. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 287, R465-R471.
3. Zheng, J.; Shan, Y.; Lambrecht, R.W.; Donohue, S.E.; Bonkovsky, H.L. Differential regulation of human ALAS1 mRNA and protein levels by heme and cobalt protoporphyrin. Mol. Cell Biochem. 2008, 319, 153-161.
4. Kolluri, S.; Sadlon, T.J.; May, B.K.; Bonkovsky, H.L. Haem repression of the housekeeping 5-aminolaevulinic acid synthase gene in the hepatoma cell line LMH. Biochem. J. 2005, 392, 173-180.
5. Handschin, C.; Lin, J.; Rhee, J.; Peyer, A.K.; Chin, S.; Wu, P.H.; Meyer, U.A.; Spiegelman, B.M. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell 2005, 122, 505-515.
6. Wu, Z.; Puigserver, P.; Andersson, U.; Zhang, C.; Adelmant, G.; Mootha, V.; Troy, A.; Cinti, S.; Lowell, B.; Scarpulla, R.C. et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999, 98, 115-124.
7. Virbasius, J.V.; Scarpulla, R.C. Activation of the human mitochondrial transcription factor A gene by nuclear respiratory factors: A potential regulatory link between nuclear and mitochondrial gene expression in organelle biogenesis. Proc. Natl. Acad. Sci. USA 1994, 91, 1309-1313.
8. Doss, M.; Verspohl, F. The “glucose effect” in acute hepatic porphyrias and in experimental porphyria. Klin. Wochenschr. 1981, 59, 727-735.
9. Scassa, M.E.; Guberman, A.S.; Ceruti, J.M.; Cánepa, E.T. Hepatic nuclear factor 3 and nuclear factor 1 regulate 5-aminolevulinate synthase gene expression and are involved in insulin repression. J. Biol. Chem. 2004, 279, 28082-28092.
10. Scassa, M.E.; Guberman, A.S.; Varone, C.L.; Cánepa, E.T. Phosphatidylinositol 3-kinase and Ras/mitogen-activated protein kinase signaling pathways are required for the regulation of 5-aminolevulinate synthase gene expression by insulin. Exp. Cell Res. 2001, 271, 201-213.
11. Anderson, K.E.; Bloomer, J.R.; Bonkovsky, H.L.; Kushner, J.P.; Pierach, C.A.; Pimstone, N.R.; Desnick, R.J. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann. Intern. Med. 2005, 142, 439-450.
12. Phillips, J.D.; Kushner, J.P. Fast track to the porphyrias. Nat. Med. 2005, 11, 1049-1050.
13. Wu, N.; Yin, L.; Hanniman, E.A.; Joshi, S.; Lazar, M.A. Negative feedback maintenance of heme homeostasis by its receptor, Rev-erbalpha. Genes Dev. 2009, 23, 2201-2209.
14. Fraser, D.J.; Podvinec, M.; Kaufmann, M.R.; Meyer, U.A. Drugs mediate the transcriptional activation of the 5-aminolevulinic acid synthase (ALAS1) gene via the chicken xenobiotic-sensing nuclear receptor (CXR). J. Biol. Chem. 2002, 277, 34717-34726.
15. Fraser, D.J.; Zumsteg, A.; Meyer, U.A. Nuclear receptors constitutive androstane receptor and pregnane X receptor activate a drug-responsive enhancer of the murine 5-aminolevulinic acid synthase gene. J. Biol. Chem. 2003, 278, 39392-39401.
16. Podvinec, M.; Handschin, C.; Looser, R.; Meyer, U.A. Identification of the xenosensors regulating human 5-aminolevulinate synthase. Proc. Natl. Acad. Sci. USA 2004, 101, 9127-9132.
17. Roberts, A.G.; Elder, G.H. Alternative splicing and tissue-specific transcription of human and rodent ubiquitous 5-aminolevulinate synthase (ALAS1) genes. Biochim. Biophys. Acta 2001, 1518, 95-105.
18. Roberts, A.G.; Redding, S.J.; Llewellyn, D.H. An alternatively-spliced exon in the 5′-UTR of human ALAS1 mRNA inhibits translation and renders it resistant to haem-mediated decay. FEBS Lett. 2005, 579, 1061-1066.
19. Lathrop, J.T.; Timko, M.P. Regulation by heme of mitochondrial protein transport through a conserved amino acid motif. Science 1993, 259, 522-525.
20. Dailey, T.A.; Woodruff, J.H.; Dailey, H.A. Examination of mitochondrial protein targeting of haem synthetic enzymes: In vivo identification of three functional haem-responsive motifs in 5-aminolaevulinate synthase. Biochem. J. 2005, 386, 381-386.
21. Munakata, H.; Munakata, H.; Sun, J.Y.; Yoshida, K.; Nakatani, T.; Honda, E.; Hayakawa, S.; Furuyama, K.; Hayashi, N.. Role of the heme regulatory motif in the heme-mediated inhibition of mitochondrial import of 5-aminolevulinate synthase. J. Biochem. 2004, 136, 233-238.
22. Tian, Q.; Li, T.; Hou, W.; Zheng, J.; Schrum, L.W.; Bonkovsky, H.L. Lon peptidase 1 (LONP1)-dependent breakdown of mitochondrial 5-aminolevulinic acid synthase protein by heme in human liver cells. J. Biol. Chem. 2011, 286, 26424-26430.
23. Ogawa, K.; Sun, J.; Taketani, S.; Nakajima, O.; Nishitani, C.; Sassa, S.; Hayashi, N.; Yamamoto, M.; Shibahara, S.; Fujita, H. et al. Heme mediates derepression of Maf recognition element through direct binding to transcription repressor Bach1. EMBO J. 2001, 20, 2835-2843.
24. Shan, Y.; Lambrecht, R.W.; Ghaziani, T.; Donohue, S.E.; Bonkovsky, H.L. Role of Bach-1 in regulation of heme oxygenase-1 in human liver cells: Insights from studies with small interfering RNAS. J. Biol. Chem. 2004, 279, 51769-51774.
25. Hou, W.; Shan, Y.; Zheng, J.; Lambrecht, R.W.; Donohue, S.E.; Bonkovsky, H.L. Zinc mesoporphyrin induces rapid and marked degradation of the transcription factor Bach1 and up-regulates HO-1. Biochim. Biophys. Acta 2008, 1779, 195-203.
26. Alam, J.; Stewart, D.; Touchard, C.; Boinapally, S.; Choi, A.M.; Cook, J.L. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J. Biol. Chem. 1999, 274, 26071-26078.
27. Alam, J.; Camhi, S.; Choi, A. Identification of a second region upstream of the mouse heme oxygenase-1 gene that functions as a basal level and inducer-dependent transcription enhancer. J. Biol. Chem. 1995, 270, 11977-11984.
28. Camhi, S.L.; Alam, J.; Otterbein, L.; Sylvester, S.L.; Choi, A.M. Induction of heme oxygenase-1 gene expression by lipopolysaccharide is mediated by AP-1 activation. Am. J. Respir. Cell Mol. Biol. 1995, 13, 387-398.
29. Hou, W.; Tian, Q.; Zheng, J.; Bonkovsky, H.L. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology 2010, 51, 1494-1504.
30. Gottwein, E.; Mukherjee, N.; Sachse, C.; Frenzel, C.; Majoros, W.H.; Chi, J.T.; Braich, R.; Manoharan, M.; Soutschek, J.; Ohler, U. et al. A viral microRNA functions as an orthologue of cellular miR-155. Nature 2007, 450, 1096-1099.
31. Pulkkinen, K.H.; Yla-Herttuala, S.; Levonen, A.L. Heme oxygenase 1 is induced by miR-155 via reduced BACH1 translation in endothelial cells. Free Radic. Biol. Med. 2011, 51, 2124-2131.
32. Hou, W.; Tian, Q.; Steuerwald, N.M.; Schrum, L.W.; Bonkovsky, H.L. The let-7 microRNA enhances heme oxygenase-1 by suppressing Bach1 and attenuates oxidant injury in human hepatocytes. Biochim. Biophys. Acta 2012, 1819, 1113-1122.
33. Chen, Y.H.; Lin, S.J.; Lin, M.W.; Tsai, H.L.; Kuo, S.S.; Chen, J.W.; Charng, M.J.; Wu, T.C.; Chen, L.C.; Ding, Y.A. et al. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum. Genet. 2002, 111, 1-8.
34. Kaneda, H.; Ohno, M.; Taguchi, J.; Togo, M.; Hashimoto, H.; Ogasawara, K.; Aizawa, T.; Ishizaka, N.; Nagai, R. Heme oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 1680-1685.
35. Exner, M.; Minar, E.; Wagner, O.; Schillinger, M. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic. Biol. Med. 2004, 37, 1097-1104.
36. Liang, K.W.; Sheu, W.H.; Lee, W.L.; Lee, I.T.; Lin, S.Y.; Ting, C.T.; Lee WJ. Shorter, G.T. Repeats in the heme oxygenase-1 gene promoter are associated with a lower severity score in coronary artery disease. J. Chin. Med. Assoc. 2013, 76, 312-318.
37. Yamada, N.; Yamaya, M.; Okinaga, S.; Nakayama, K.; Sekizawa, K.; Shibahara, S.; Sasaki, H. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am. J. Hum. Genet. 2000, 66, 187-195.
38. Bonkovsky, H.L.; Lambrecht, R.W.; Naishadham, D. Genetic variations in heme oxygenase-1 and chronic hepatitis. Hepatology 2010, 52, 400-401.
39. Ambros,V. The functions of animal microRNAs. Nature 2004, 431, 350-355.
40. Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009, 136, 215-233.
41. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281-297.
42. Beckman, J.D.; Chen, C.; Nguyen, J.; Thayanithy, V.; Subramanian, S.; Steer, C.J.; Vercellotti, G.M. Regulation of heme oxygenase-1 protein expression by miR-377 in combination with miR-217. J. Biol. Chem. 2011, 286, 3194-3202.
43. Kramer, M.; Sponholz, C.; Slaba, M.; Wissuwa, B.; Claus, R.A.; Menzel, U.; Huse, K.; Platzer, M.; Bauer, M. Alternative 5′ untranslated regions are involved in expression regulation of human heme oxygenase-1. PLoS One 2013, 8, Article e77224.
44. Schmid, R.; Schwartz, S.; Watson, C.J. Porphyrin content of bone marrow and liver in the various forms of porphyria. AMA Arch. Intern. Med. 1954, 93, 167-190.
45. Doss, M.; von Tiepermann, R.; Schneider, J.; Schmid, H. New type of hepatic porphyria with porphobilinogen synthase defect and intermittent acute clinical manifestation. Klin. Wochenschr. 1979, 57, 1123-1127.
46. Waldenstrom, J. The porphyrias as inborn errors of metabolism. Am. J. Med. 1957, 22, 758-773.
47. Tschudy, D.P.; Valsamis, M.; Magnussen, C.R. Acute intermittent porphyria: Clinical and selected research aspects. Ann. Intern. Med. 1975, 83, 851-864.
48. Floderus, Y.; Shoolingin-Jordan, P.M.; Harper, P. Acute intermittent porphyria in Sweden. Molecular, functional and clinical consequences of some new mutations found in the porphobilinogen deaminase gene. Clin. Genet. 2002, 62, 288-297.
49. Moore, M.R.; McColl, K.E.L.; Rimington, C.; Goldberg, A. Disorders of Porphyrin Metabolism; Plenum Medical Book Company: New York, NY, USA, 1987.
50. Mustajoki, P.; Koskelo, P. Hereditary hepatic porphyria in Finland. Acta Med. Scand. 1976, 200, 171-178.
51. Schneider-Yin, X.; Harms, J.; Minder, E.I. Porphyria in Switzerland:15 Years’ experience. Swiss Med. Wkly. 2009, 139, 198-206.
52. Lamon, J.M.; Frykholm, B.C.; Tschudy, D.P. Family evaluations in acute intermittent porphyria using red cell uropophyrinogen I synthase. J. Med. Genet. 1979, 16, 134-139.
53. Vonundzu Fraunberg, M.; Pischik, E.; Udd, L.; Kauppinen, R. Clinical and biochemical characteristics and genotype-phenotype correlation in 143 Finnish and Russian patients with acute intermittent porphyria. Medicine 2005, 84, 35-47.
54. Nordmann, Y.; Puy, H.; da Siva, V.; Simonin, S.; Robreau, A.M.; Bonaiti, C.; Phung, L.N.; Deybach, J.-C. Acute intermittent porphyria: The prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France. J. Int. Med. 1997, 242, 213-217.
55. Elder, G.; Harper, P.; Badminton, M.; Sandberg, S.; Deybach, J.C. The incidence of inherited porphyrias in Europe. J. Inherit. Metab. Dis. 2013, 36, 849-857.
56. Schneider-Yin, X.; Harms, J.; Minder, E.I. Porphyria in Switzerland, 15 years experience. Swiss Med. Wkly. 2009, 139, 198-206.
57. Hultdin, J.; Schmauch, A.; Wikberg, A.; Dahlquist, G.; Andersson, C. Acute intermittent porphyria in childhood: A population-based study. Acta Paediatr. 2003, 92, 562-568.
58. American Porphyria Foundation. Available online: http://www.porphyriafoundation.com/ drug-database (accessed on 29 October 2014).
59. European Porphyria Network. Available online: http://www.porphyria-europe.org (accessed on 29 October 2014).
60. University of Cape Town Porphyria Service. Available online: http://www.porphyria.uct.ac.za (accessed on 29 October 2014).
61. Bonkovsky, H.L.; Guo, J.T.; Hou, W.; Li, T.; Narang, T.; Thapar, M. Porphyrin and heme metabolism and the porphyrias. Compr. Physiol. 2013, 3, 365-401.
62. Puy, H.; Gouya, L.; Deybach, J.C. Porphyrias. Lancet 2010, 375, 924-937.
63. Kauppinen, R.; Mustajoki, P. Prognosis of acute porphyria: Occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltim.) 1992, 71, 1-13.
64. Bonkovsky, H.L.; Maddukuri, V.C.; Yazici, C.; Anderson, K.E.; Bissell, D.M.; Bloomer, J.R.; Phillips, J.D.; Naik, H.; Peter, I.; Baillargeon, G. et al. Acute Porphyrias in the USA: Features of 108 Subjects from Porphyria Consortium. Am. J. Med. 2014, 9, doi:10.1016/j.amjmed.2014.06.036.
65. Goldberg, A. Acute intermittent porphyria: A study of 50 cases. Q. J. Med. 1959, 28, 183-209.
66. Nordmann, Y.; Puy, H. Human hereditary hepatic porphyrias. Clin. Chim. Acta 2002, 325, 17-37.
67. Bloomer, J.R.; Bonkovsky, H.L. The porphyrias. Dis Mon. 1989, 35, 1-54.
68. Sardh, E.; Andersson, D.E.; Henrichson, A.; Harper, P. Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes. Cell. Mol. Biol. 2009, 55, 66-71.
69. Deacon, A.C.; Peters, T.J. Identification of acute porphyria: Evaluation of a commercial screening test for urinary porphobilinogen. Ann. Clin. Biochem. 1998, 35, 726-732.
70. Bonkovsky, H.L. Porphyrin and Heme Metabolism and Porphyrias. In HEPATOLOGY: A Textbook of LIVER DISEASE, 2nd ed.; Zakim, D., Boyer, T.D., Eds.; Saunders: Philadelphia, PA, USA, 1990; pp. 378-424.
71. Bonkovsky, H.L.; Barnard, G.F. Diagnosis of porphyric syndromes: A practical approach in the era of molecular biology. Semin. Liver Dis. 1998, 18, 57-65.
72. Hahn, M.; Bonkovsky, H.L. Disorders of porphyrin metabolism. Diseases of the Liver and Bile Ducts: A Practical Guide to Diagnosis and Treatment, 1 st ed.; Wu, G., Israel, J., Totowa, N.J., Eds.; Humana Press: New York, NY, USA, 1998; pp. 249-272.
73. The Human Gene Mutation Datbase at the Institute of Medical Genetics in Cardiff. Available online:http://www.hgmd.cf.ac.uk/ac/index.php (accessed on 29 October 2014).
74. Anderson, K.E.; Bonkovsky, H.L.; Bloomer, J.R.; Shedlofsky, S.I. Reconstitution of hematin for intravenous infusion. Ann. Intern. Med. 2006, 144, 537-538.
75. Bonkovsky, H.L.; Healey, J.F.; Lourie, A.N.; Gerron, G.G. Intravenous heme-albumin in acute intermittent porphyria: Evidence for repletion of hepatic hemoproteins and regulatory heme pools. Am. J. Gastroenterol. 1991, 86, 1050-1056.
76. Dar, F.S.; Asai, K.; Haque, A.R.; Cherian, T.; Rela, M.; Heaton, N. Liver transplantation for acute intermittent porphyria: A viable treatment? Hepatobiliary Pancreat. Dis. Int. 2010, 9, 93-96.
77. Seth, A.K.; Badminton, M.N.; Mirza, D.; Russell, S.; Elias, E. Liver transplantation for porphyria: Who, when, and how? Liver Transpl. 2007, 13, 1219-1227.
78. Wahlin, S.; Harper, P.; Sardh, E.; Andersson, C.; Andersson, D.E.; Ericzon, B.G. Combined liver and kidney transplantation in acute intermittent porphyria. Transpl. Int. 2010, 23, e18-e21.
79. Mercelis, R.; Hassoun, A.; Verstraeten, L.; De Bock, R.; Martin, J.J. Porphyric neuropathy and hereditary delta-aminolevulinic acid dehydratase deficiency in an adult. J. Neurol. Sci. 1990, 95, 39-47.
80. Elder, G.H. Porphyria cutanea tarda. Semin. Liver Dis. 1998, 18, 67-75.
81. Brady, J.J.; Jackson, H.A.; Roberts, A.G.; Morgan, R.R.; Whatley, S.D.; Rowlands, G.L.; Darby, C.; Shudell, E.; Watson, R.; Paiker, J. et al. Co-inheritance of mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria cutanea tarda. J. investig. Dermatol. 2000, 115, 868-874.
82. Bonkovsky, H.L. Mechanism of iron potentiation of hepatic uroporphyria: Studies in cultured chick embryo liver cells. Hepatology 1989, 10, 354-364.
83. Phillips, J.D.; Bergonia, H.A.; Reilly, C.A.; Franklin, M.R.; Kushner, J.P. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc. Natl. Acad. Sci. USA 2007, 104, 5079-5084.
84. Badminton, M.N.; Elder, G.H. Molecular mechanisms of dominant expression in porphyria. J. Inherit. Metab. Dis. 2005, 28, 277-286.
85. Bonkovsky, H.L.; Poh-Fitzpatrick, M.; Pimstone, N.; Obando, J.; Di Bisceglie, A.; Tattrie, C.; Tortorelli, K.; LeClair, P.; Mercurio, M.G.; Lambrecht, R.W. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998, 27, 1661-1669.
86. Gisbert, J.P.; Garcia-Buey, L.; Pajares, J.M.; Moreno-Otero, R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: Systematic review and meta-analysis. J. Hepatol. 2003, 39, 620-627.
87. Fargion, S.; Piperno, A.; Cappellini, M.D.; Sampietro, M.; Fracanzani, A.L.; Romano, R.; Caldarelli, R.; Marcelli, R.; Vecchi, L.; Fiorelli, G. Hepatitis C virus and porphyria cutanea tarda: Evidence of a strong association. Hepatology 1992, 16, 1322-1326.
88. Pätzold, K.; Hahn, L.; Lohmann, J.; Porst, H. Liver cirrhosis and chronic hepatic porphyria. Z Gastroenterol. 1993, 31 (Suppl. S2), 114-115.
89. Gisbert, J.P.; García-Buey, L.; Alonso, A.; Rubio, S.; Hernández, A.; Pajares, J.M.; García-Díez, A.; Moreno-Otero, R. Hepatocellular carcinoma risk in patients with porphyria cutanea tarda. Eur. J. Gastroenterol. Hepatol. 2004, 16, 698-692.
90. Ippen, H. Treatment of porphyria cutanea tarda by phlebotomy. Semin. Hematol. 1977, 14, 253-259
91. Tavill, AS. Diagnosis and management of hemochromatosis. Hepatology 2001, 33, 1321-1328.
92. Singal, A.K.; Kormos-Hallberg, C.; Lee, C.; Sadagoparamanujam, V.M.; Grady, J.J.; Freeman, D.H., Jr.; Anderson, K.E. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin. Gastroenterol. Hepatol. 2012, 10, 1402-1409.
93. Marchesi, L.; Di Padova, C.; Cainelli, T.; Reseghetti, A.; Di Padova, F.; Rovagnati, P.; Cantoni, L. A comparative trial of desferrioxamine and hydroxychloroquine for treatment of porphyria cutanea tarda in alcoholic patients. Photodermatol 1984, 1, 286-292.
94. Pandya, A.G.; Nezafati, K.A.; Ashe-Randolph, M.; Yalamanchili, R. Deferasirox for porphyria cutanea tarda: A pilot study. Arch. Dermatol. 2012, 148, 898-901.
95. Kordac, V.; Semrádová, M. Treatment of porphyria cutanea tarda with chloroquine. Br. J. Dermatol. 1974, 90, 95-100.
96. Freesemann, A.; Frank, M.; Sieg, I.; Doss, M.O. Treatment of porphyria cutanea tarda by the effect of chloroquine on the liver. Skin Pharmacol. 1995, 8, 156-161.
97. Shady, A.A.; Colby, B.R.; Cunha, L.F.; Astrin, K.H.; Bishop, D.F.; Desnick, R.J. Congenital erythropoietic porphyria: Identification and expression of eight novel mutationsin the uroporphyrinogen III synthase gene. Br. J. Haematol. 2002, 117, 980-987.
98. Xu, W.; Warner, C.A.; Desnick, R.J. Congenital erythropoietic porphyria: Identification and expression of 10 mutations in the uroporphyrinogen III synthase gene. J. Clin. Investig. 1995, 95, 905-912.
99. Fontanellas, A.; Bensidhoum, M.; Enriquez de Salamanca, R.; Moruno Tirado, A.; de Verneuil, H.; Ged, C. A systematic analysis of the mutations of the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria. Eur. J. Hum. Genet. 1996, 4, 274.
100. Meguro, K.; Fujita, H.; Ishida, N.; Akagi, R.; Kurihara, T.; Galbraith, R.A.; Kappas, A.; Zabriskie, J.B.; Toback, A.C.; Harber, L.C. Molecular defects of uroporphyrinogen decarboxylase in a patient with mild hepatoerythropoietic porphyria. J. Investig Dermatol. 1994, 102, 681-685.
101. Balwani, M.; Desnick, R.J. The porphyrias: Advances in diagnosis and treatment. Blood 2012, 120, 4496-4504.
102. Singh, S.; Khanna, N.; Kumar, L. Bone marrow transplantation improves symptoms of congenital erythropoietic porphyria even when done post puberty. Indian J. Dermatol. Venereol. Leprol. 2012, 78, 108-111.
103. Martinez Peinado, C.; Díaz de Heredia, C.; To-Figueras, J.; Arias-Santiago, S.; Nogueras, P.; Elorza, I.; Olivé, T.; Bádenas, C.; Moreno, M.J.; Tercedor, J. et al. Successful treatment of congenital erythropoietic porphyria using matched unrelated hematopoietic stem cell transplantation. Pediatr. Dermatol. 2013, 30, 484-489.
104. Whatley, S.D.; Ducamp, S.; Gouya, L.; Grandchamp, B.; Beaumont, C.; Badminton, M.N.; Elder, G.H.; Holme, S.A.; Anstey, A.V.; Parker, M. et al. C-terminal deletions in the q ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am. J. Hum. Genet. 2008, 83, 408-414.
105. Magnus, I.A.; Jarrett, A.; Prankerd, T.A.; Rimington, C. Erythropoietic protoporphyria. A new porphyria syndrome with solar urticaria due to protoporphyrinaemia. Lancet 1961, 2, 448-451.
106. Harms, J.; Lautenschlager, S.; Minder, C.E.; Minder, E.I. An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. N. Engl. J. Med. 2009, 360, 306-307.
107. Harms, J.H.; Lautenschlager, S.; Minder, C.E.; Minder, E.I. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. Photochem. Photobiol. 2009, 85, 1434-1439.
108. Minder, E.I. Afamelanotide, an agonistic analog of alpha-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria. Expert Opin. Investig. Drugs 2010, 19, 1591-602.
109. Pirlich, M.; Lochs, H.; Schmidt, H.H. Liver cirrhosis in erythropoietic protoporphyria: Improvement of liver function with ursodeoxycholic acid. Am. J. Gastroenterol. 2001, 96, 3468-3469.
110. Abitbol, M.; Puy, H.; Sabaté, J.M.; Guénet, J.L.; Deybach, J.C.; Montagutelli, X. Ursodesoxycholic acid and heme-arginate are unable to improve hematopoiesis and liver injury in an erythropoietic protoporphyria mouse model. Physiol. Res. 2006, 55 (Suppl. S2), S93-S101.
111. Crooks, D.R.; Ghosh, M.C.; Haller, R.G.; Tong, W.H.; Rouault, T.A. Posttranslational stability of the heme biosynthetic enzyme ferrochelatase is dependent on iron availability and intact iron-sulfur cluster assembly machinery. Blood 2010, 115, 860-869.
112. Bentley, D.P.; Meek, E.M. Clinical and biochemical improvement following low-dose intravenous iron therapy in a patient with erythropoietic protoporphyria. Br. J. Haematol. 2013, 163, 289-2291.
113. Milligan, A.; Graham-Brown, R.A.; Sarkany, I.; Baker, H. Erythropoietic protoporphyria exacerbated by oral iron therapy. Br. J. Dermatol. 1988, 119, 63-66.
114. McClements, B.M.; Bingham, A.; Callender, M.E.; Trimble, E.R. Erythropoietic protoporphyria and iron therapy. Br. J. Dermatol. 1990, 122, 423-424.
115. McGuire, B.M.; Bonkovsky, H.L.; Carithers, R.L., Jr.; Chung, R.T.; Goldstein, L.I.; Lake, J.R.; Lok, A.S.; Potter, C.J.; Rand, E.; Voigt, M.D. et al. Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl. 2005, 11, 1590-1596.